Zydus Lifesciences Limited | ESG Report 2021-22













To unlock new possibilities in life-sciences through quality healthcare solutions that impact lives



Be a global Life-sciences company transforming lives through pathbreaking discoveries



Empower People with the freedom to live healthier and more fulfilled lives





After a journey of growth spanning 27 years, we have evolved and transformed ourselves in response to the changing times.

The pandemic brought Zydus closer to our purpose than ever before. Our mission, vision and purpose aim at increasing the access to healthcare by focussing on science and innovation. Our journey as a responsible organisation through the years has been marked by a conscious effort to contribute to the welfare of the communities, people and the world around us. Through our initiatives under ESG we reaffirm this commitment and remain dedicated to life in all its dimensions.

Mr. Pankaj Patel

Chairman Zydus Lifesciences Ltd.






At Zydus, our core purpose is to empower people with the freedom to live healthier and more fulfilled lives.

Continuous improvement and sustainable approaches to ESG goals are an integral part of it. Whether it is through safe manufacturing practises, protecting the ecosystem, making people an active part of our growth, celebrating diversity at the workplace, bringing in access and affordability through innovation, focusing on patient centricity, bridging unmet healthcare needs, standing true to our values and core behaviours of respect, trust and integrity which also reflects in our governance and the way we work. We will continue to build and nurture the communities we form a part of.

Dr. Sharvil Patel

Managing Director Zydus Lifesciences Ltd.








ESG **MATERIALITY MATRIX** 2021-22


ESG Materiality Approach

- ESG Standards Peer Benchmarking

 - Business Value Stakeholder discussions
 - Chain Analysis











ESG FACT SHEETS 2021-22

ESG Report 2021-22 | 11



Environment



Overview

The world continues to face the challenges like global pandemic, Russian –Ukraine war and its impacts on climate change is crucial, there is greater urgency and action needed in this area.

We at Zydus Lifesciences Ltd. (Formerly Known as Cadila Healthcare Ltd.) believe that protecting people and the planet is our core value & mission to create healthy communities globally.

Combatting climate change requires action, innovation and a multi-faceted, collaborative approach. We remain committed towards resource conservation in the area of

Energy I Fuel I Water I Waste including Co-processing activity for energy recovery.



to Environment and Environment Protection is an ongoing journey.



Environmental violations of legal regulations

With help of internal & external experts, we adopt continuous improvement in waste management by implementing **"wealth from waste"** strategy. We also recognize the unique and evolving characteristics of climate risk, which include longer time horizons, changing magnitudes and nonlinear dynamics requirement, may be differential assessment and management strategies for each of businesses and verticals.

Water Management:

We efficiently manage the Fresh water consumption at manufacturing plants through continuously monitoring, reviewing and optimising process modifications and adoption of new technologies. In FY 2021-22 water dependency on ground water usage reduced to 34% Compare to 55.75% for FY 2020-2021

State of the local division in the local div	and the second second	Environmental Indicator	Descrip	tion		Zydus Lifesciences
1 49-20		Total Water withdrawn (KL)	Total water wit	hdrawn		14,57,476
al to	No. of Concession, Name		Municipal (Third Party)			6,12,838
1000	and the second		Ground water			5,06,320
AND INCOMENT	and the second		Surface wate	r		3,38,318
A STATE OF STATE			Units In water s	tressed areas		2
	and the		Water from wa	ter stressed area	5	1,62,368
1 S			Total water con	sumed (KL)		7,78,157
/ater Source (KL)		Ground Water	Surface	Water	Third Party	
otal Water (KL) Yithdrawn	FY2019-2020	8,04,	.359	7.224	5,35,388	
2021-2022			,	.,		
4,57,476 🗸	FY2020-202	8,57,1	55	1,09,731	5,71,700	
2020-2021 15,38,586						
	FY2021-2022	5,06,320	3,38,3	18	6,12,838	
2019-2020 13,46,971			_,,_			
Effluent		e reuse 46% total water consump	6		The treated w discharge to tl	hird party is
			otion		The treated w discharge to th 3,40,234	hird party is 4 KL
Effluent			otion	Effluent Reus	The treated w discharge to th 3,40,234 se Treate	hird party is 4 KL
		total water consump	otion	Effluent Reus	The treated w discharge to th 3,40,234 se Treate	4 KL ed effluent discharge
Effluent		total water consump	otion (Effluent Reus	The treated w discharge to th 3,40,234 Se Treate to thir	hird party is 4 KL ed effluent discharge d party
Effluent		total water consump	otion Contracted 0 019-2020	Effluent Reus	The treated w discharge to th 3,40,234 Se Treate to thin 7,04,361	hird party is 4 KL ed effluent discharge d party 3,17,960
Effluent Managemer		total water consump	otion Treated 019-2020 020-2021 021-2022	Effluent Reus	The treated w discharge to th 3,40,234 Se Treate to thin 7,04,361 7,85,138 5,79,319	hird party is 4 KL ed effluent discharge d party 3,17,960 3,34,720
Effluent Managemer	nt (KL) of	total water consump	otion Created 019-2020 020-2021 021-2022 2	Effluent Reus	The treated w discharge to th 3,40,234 Se Treate to thin 7,04,361 7,85,138 5,79,319	hird party is 4 KL ed effluent discharge d party 3,17,960 3,34,720
Effluent	ht (KL) of	total water consump FY2 FY2 FY2	otion Contract of the second s	Effluent Reus kullenseiences 0,19,553 (40,234	The treated w discharge to th 3,40,234 Se Treate to thin 7,04,361 7,85,138 5,79,319	hird party is 4 KL ed effluent discharge d party 3,17,960 3,34,720

Hazardous Waste Management:

We have be	een working o	n		Land fill	Incineration	Recy	rcle 🗖 Co- Pr	ocessing
4 R pri	nciples			FY2019-2020	3,503 9	32	3,790	2,215
\mathcal{C}		स्र	G,	FY2020-2021	3,407	619	4,513	2,631
Reduce	Reuse e waste and in	Recycle crease resource	Recover e efficiency.	FY2021-2022	3,694	486	7,272	2,812
In FY22 Re	cycle of waste	e is 51% .						

Co-Processing at cement kiln is 20%, Incineration is 3% and, Landfill is 26%

The increase in waste generation is due to the new projects and current expansion of the units.

Non-Hazardous Waste Management:



100% of

non-hazardous waste is disposed to authorised vendor

Environmental Indicator	Description	Zydus Lifesciences
Total Waste (Thousand tonnes)		14,685
Hazardous Waste (MT)	Disposal in Landfills	3,694
	Incinerated	486
	Recycle	7,272
	Co Processing	2,812
E Waste (MT)	Generated	28
	Recycle	26
Battery Waste (MT)	Generated	26
	Recycle	26
Bio Medical Waste (MT)	Generated	285
	Incinerated	283
	Recycle	2
Non-Hazardous waste (MT)	Total waste (tonnes) generated and recycled /reuse	4,789


Energy and GHG Emissions Management:

We have started the mapping and working on new technologies for energy and GHG emission management. The increase in the energy consumption and GHG emission is due to the new projects and current expansion of the units.


We have entered into an Agreement for setting up captive Wind Solar Hybrid power project in Gujarat to increase their renewable energy mix.




Total Energy Consumption (MWh)



Total Non-Renewable Energy Consumption (MWh)



Total Renewable Energy Consumption (MWh)



Environmental Indicator	Description	Zydus Lifesciences
Total Energy for operations (MWh)	Total Energy	4,91,128
	Purchased Renewable Electricity	6000
	Purchased Non - Renewable Energy (A+B)	4,85,128
	Total fuel consumption (A)	2,75,492
	Natural Gas purchased	11,698
	Coal	1,66,937
	Briquette	85,153
	Other Fossil Fuel (diesel, FO)	11,704
	Renewable heat	NIL
	Steam	NIL
	Purchased Non - Renewable Electricity (B)	2,09,634

GHG Emissions and Carbon Targets

Total GHG emissions		2,55,889 Tonnes
Scope 1: Emission by Source	On-site fuel use (tonnes CO2 e)	89,627 Tonnes
Scope 2: Emission by Source	Electricity (market-based emissions) (thousands of tonnes CO2 e)	1,66,262 Tonnes
Scope 3 Emissions		In progress

Biodiversity



Zydus Life Sciences Limited takes deliberate efforts for conserving biodiversity and work for impactful biodiversity enhancement.

No species listed in the International Union for Conservation of Nature (IUCN) Red List and National Conservation List was found to be exist in or near the manufacturing units. All units are located outside biodiversity sensitive or notified protected areas; hence there is no such case of habitats affected by discharges of water and runoff from the unit.

While setting up new factories / units or during retrofitting / expansion, We are taking due consideration towards Biological Diversity Act and Rules. We are dedicated and maintaining the dense and opulent green belts across all the manufacturing units as per legal requirement and understand flora as natural purifier for their ability to take CO2 from the atmosphere.

Planting and maintaining trees is recognized as strategy adopted for decarbonizing and guarding biodiversity.






trees were planted in Company premise in last three years for protecting the biodiversity

Environmental Indicator	Zydus Lifesciences
Total Trees Planted during FY 21-22	1797

The biodiversity drive is not limited to the company but has also extended to society by distributed and encourage the employees for the plantation at their places.



Social



As a strategic business partner for growth, Zydus HR has been building organisational capabilities to deliver the desired business outcomes and acting as the catalyst for maximising the value in the organisation. At the heart of it all are initiatives which create an eco-system within the organisation that spurs transformation and change. The team has been leading several initiatives for organisational change, process agility, digitization, enhancing employee experience, building organisational capability and strengthening the impact of HR on business outcomes. All this leading to a stronger value proposition for the employees, business partners, stakeholders and customers. The year 2021-2022 was dedicated to organisational transformation and change towards building the Zydus of the future.

As a part of a larger transformation process, HR is focussing on creating an environment conducive for value creation, innovation, collaboration and growth. Creating people assets and investing in capability building have been at the heart of the organization's growth since 1995. Team HR has been looking at both conventional and differentiated approaches to create this culture of learning in the Company. Continuous capability building by skilling, re-skilling and up-skilling has been an ongoing process. Leadership development and strengthening the leadership bench strength is also an area of focus. Today the group has 495 leadership role holders. In a collaborative approach, our HR processes facilitate performance discussions every six months in a constructive way by linking performance dialogue with KPIs and enterprise score card. The Zyscore and Myscore discussions underline the sustainable business performance and outcome focussed culture at Zydus. The group has been consistently announcing its performance rewards and increments at the end of every financial year making it a unique aspect of its people-centric approach.


Combining the HR strategy with more efficient processes for delivery and execution, Zydus HR is creating a more agile and future ready organisation. The group recruits young and talented management graduates from premier institutes as trainees in the technical and corporate functions. The Zydus Group Resources Programme is successfully creating a future talent pipeline for the organisation.



12,110	No. of Employees, India (ZLL)
--------	-------------------------------


- **3** No. of Employees, Global (ZLL)
- 12,113 Total Employees (ZLL)





Age Diversity: Average Age of Employees

Zydus Life Sciences




	Asian (Indian)	Others (Asian, US)		
Nationality Diversity	99.9998%	0.0002%		
Share in all management positions, including junior, middle and senior management (as % of total management workforce)	99.9998%	0.0002%		
Growth in Median salary of emp	oloyees (Y-o-Y) 8.53%		
Gender Pay Indicator (Male vs F	emale)	Mean geno	ler pay gap	7%
		Median ge	nder pay gap	-3%









Health & Safety



OHS

As per EHS Policy, strive to achieve ZERO HARM target in terms of Incident and Injuries to people. Ensuring good health and safety of all employee is primary commitment and goal. We make consistent approach in safety-focused programmes and controls to strengthen our safety management system.

We are creating a safer work place through various safety awareness campaign such as publishing safety booklet (Near Miss, Process Safety, Hazards of Nitrogen, Toolbox Talk and Static Electricity), EHS Theme base working, EHS pictorial messages, EHS Days celebration. New and amendment Act, Rules, Guidelines, Achievements related to EHS are regularly updated biyearly on the Zydus EHS Portal.

All our manufacturing facilities have implemented safety management systems through Zysafe software (http://zysafe/login.aspx). All the employees has access of Zysafe software. Zysafe software consists of 9 different modules for EHS Scheduling, Observations, Corrective Action Preventive Action (CAPA), Incident and Investigation, EHS Monthly Report, Global CAPA, Work Permit, Safety Passport, EHS Quiz.



20 | ESG Report 2021-22

CSR

Aligning its mission and corporate social responsibility, the Company continues to create healthier, happier communities globally. Zydus Shrishti, the Company's CSR programme focusses on the areas of health, education and research. Making a difference To serve the needs of the patients and bring world-class medical education to the rural interiors of Gujarat, Zydus Foundation has set up the Zydus Medical College and Hospital at Dahod. First established in 1947 as a sanatorium, the Hospital at Dahod was adopted by the Company under the Brownfield Health Policy in 2016.

Since then, the Hospital has been converted into a full-fledged hospital as per MCI norms. From 150 beds, the hospital expanded to 650 beds with over 694 professionals including doctors, nurses and paramedics offering medical care in the year 2020. The Hospital provides free treatment including OPD, hospitalisation, all investigations, surgeries, anaesthesia, oral medicines, injectables and food for patients.

CSR Spent as a % of Net profit 2%

Awareness against disease conditions

During the financial year, over 3000 awareness sessions for patients and healthcare providers (HCPs) were organised about different disease conditions including Hypertension, Liver Care, Diabetes, Gastrointestinal Diseases, Cancers, Inflammatory diseases, Nephrology, Cardiology, COVID-19, Common Cold and Flu.

Disease screening

The company also organised several camps to screen various diseases including Breast Cancer, Non-Alcoholic Fatty Liver Disease (NAFLD), Non- Alcoholic Steatohepatitis (NASH), Osteoporosis, Hepatitis and several other diseases where the company is working towards shaping better patient outcomes.



Supporting global bodies in fight against various diseases

Supporting various global bodies in creating awareness about various diseases like Hepatitis,

Non-Alcoholic Fatty Liver Disease (NAFLD), Non- Alcoholic Steatohepatitis (NASH), Cancer and other key therapy areas for the company.

Supporting global bodies in fight against diseases

- Cancer foundations
- Liver and Hepatitis Awareness
- Gastrointestinal Diseases

Camps

- Fibroscan camp · Breast Cancer Screening
- Bone Mineral Density Camp
- Hepatitis therapy camps

Total CSR Spent by Zydus Lifesciences Limited

CSR initiative Amount	for FY-22 (Rs.)
Awareness camps on blood pressure and diabetes	11,88,720
Awareness camps on cancer	1,11,95,850
Together We Fly	94,00,000
Donation to SMILE foundation - Educating underprivileged children	5,00,000
Fibroscan camps for detecting NAFLD and NASH	3,60,00,000
Skill development programme at Zydus Skill Development Centre	9,45,61,155
Screening camps for Viral Hepatitis	1,00,00,000
Coalition for Global Hepatitis Elimination	78,17,780
Global Liver Institute as part of our contribution towards	
International NASH Day aimed at raising awareness on NAFLD	78,17,780
Awareness camps for BMD	15,00,000
Supporting Breast Cancer detection through camps	
organised by Niramai	1,20,000
CSR Expenditure at Dabhasa	10,56,705
TOTAL (A)	18,11,57,990
Contributed by ZHL which is subsidiary of ZLL (B)	32,56,720
Amount contributed by ZLL (A-B)	17,79,01,270
CSR-2% mandatory contribution	27,00,00,000
Philanthropic and mandatory CSR cummulative for	
final consideration	44,79,01,270

Health Outcome Contri<u>bution</u>



Healthcare costs are growing exponentially due to aging populations and the rise of chronic diseases. Therefore, companies are under increasing pressure from governments that seek to reform healthcare systems in order to lower costs and increase healthcare efficiency. Companies that are able to quantify the value they are providing to the healthcare systems, displaying evidence that their products significantly improve health outcomes, will have a long-term competitive advantage.

Prevention	Key Programs	KPI used to measure impact (e.g. # of patients reached)	Impact FY 2021	Forecast Impact FY 2022
BioNext	Awareness Programs on Fatty Liver, Viral Hepatitis, Healthy Liver	No of patients reached both physically & through social media HCPs engaged Programs conducted	1 million patients reached 400 HCPs engaged 300 programs conducted	1 million patients reached 300 HCPs engaged 200 programs conducted
Oncology	Screening for Breast Cancer	60-70 High risk patients	Covered 300 AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA	
	Corporate Awareness program	General cancer and breast cancer awareness in corporates with help of Oncologist for their staff mainly female staff	15 such activities to cover 1000 people for awareness	
Nephrology	World Kidney Day & other patient awareness meetings (Chronic Kidney Disease Awareness Programs)	Number of programs conducted across India Number of patients impacted	4 (Patient gathering restricted due to Covid) 80 patients	0 ² 0 ² 0 42
Vaxxicare	Vaxxicare :Improving Immunisation rate (IIR) Initiative Vaccine awareness through In-clinic Art Competition to Improve the Subject-Dr Dialogue in-clinic with objective to improve awareness & adoption of vaccines.	KPI : No of Subject Engaged: "30000 KPI- Planned Implementation :1000 clinic with 50000 Subject Actual Implementation : 600+ clinics with 30000+ Subjects (Kids below 5 years) This Activity was initiated post opening of Lockdown (Post Covid) to Engage Kids Less than 5 Years & their Parents to improve Subject-Dr Dialogue on bridging the Gap of Vaccination & Improve immunisation rate	Activity helped Zydus Vaxxicare to create value with the pediatricians as Immunisation Partner who help improves vaccination rate in India with - 600+ Pead across India.	Replication of activities will help Zydus Vaxxicare to partner with 1500+ Pead across 70 Cities in 2022 touching more than 1 Lakhs S ubject & their parents on Pead, Catch-up & adult vaccination. This IIR activities help improve the education, awareness of vaccines & help improves the adoption of vaccines. This initiatives supports & strengthen the Govt vaccine awareness on ground to achieve SDG of reducing the children mortality & morbidity through adoption vaccines

Prevention	Key Programs	KPI used to measure impact (e.g. # of patients reached)	Impact FY 2021	Forecast Impact FY 2022
BioNext	Viral Hepatitis Screening camps Fibro Liver scan camps	No of Camps conducted No of patients screened No of HCPs engaged No of Patients Positive / At risk No of patients converting to therapy	Hepatitis 100 camps conducted 3000 pts screened Fibro (July - Dec) 1393 camps done, 196 doctors engaged, 9000 patients screened	Hepatitis 90 camps conducted (Till June) 3000 + patients screened Fibro (Jan – June) 1848 camps done, 260 doctors engaged, 14000 patients screened 4500 patients
Biovation	BMD camps	No. of patients screened	2115 patients	4500 patients
Oncology	Nirami touch less Screening	KOL engagement, KOL awareness talk followed by Screening		
Treatment (adherence/ compliance and rehabilitation) - Nephrology	Patient awareness programs - Organ transplant	Number of programs conducted across India Number of patients impacted	5 (Patient gathering restricted due to Covid) >100 patients	~~~~ 25
End to End Cycle Solutions / Other Program Vaxxicare	Supply of vaccines to Pediatrician with Economical Pricising Other Program: Focus on Maternal Immunisation PROMISE-PROTECTING MATERNAL & NEONATAL LIVES THROUGH INFLUENZA & other vaccines VIRAM : Full Stop on Rabies	KPI : No of Activity with OBGYN KPI : No of Women Aware KPI : Vaccine Adoption during Pregnancy	NA	NA



Governance

Category	Governance Indicator	Zydus Lifesciences
Board Matters	Board size (As on March 2022)	8
	% Independent Directors (As on March 2022)	50%
	Gender Diversity - % Women Directors	13%
	Tenure > 10 years for Independent Directors	Fixed term of 5 years (upto 2 terms)
	Average Independent Directors Tenure	7 years
	Average Board Tenure	13.6 years
	Independent Directors: Independence criteria.	Disclosed in Annual Report
	Average Age	64.38 years
	Age Diversity: 40-49 Years	12.5%
	Age Diversity: 50-59 Years	12.5%
	Age Diversity: 60-69 Years	50%
	Age Diverity: 70-79 Years	25%
	Number of Board meetings	8
	Average Attendance	98%
	Minutes of the meeting	Within 15 days
	Number of Committee Meetings	43
Board Skill	Independent Directors - Pharma Industry Experience	Yes
	Independent Directors - Financial Expertise	Yes
Board Evaluation	Board evaluation – annual (formally)	Yes
	Committee evaluation – annual (formally)	Yes
	Individual Director evaluation – annual (formally)	Yes
	Evaluation criteria – Defined and disclosed	Yes
	Questionnaire based evaluation	Yes
Audit Committee	Size of Audit Committee	5
	Independent Director as Chairperson	Yes
	Independent Directors (%) (As on March 2022)	80
	Audit Committee Charter	Yes
	Number of Audit Committee meetings	4
Nomination & Remuneration Committee	Size of Nomination & Remuneration Committee	6
	Independent Directors (%) (As on March 2022)	67%
	Independent Director as Chairperson	Yes
	NRC Charter	Yes
	Number of NRC meetings	З
Corporate Social Responsibility Committee	Size of the CSR	З
	Independent Directors (%)	33%
	Number of CSR meetings	З
	CSR Charter	Yes
SRC	Number of SRC meetings (FY21)	1



Category	Governance Indicator	Zydus Lifesciences
Risk Management Committee	Number of RMC meetings (FY21)	1
	Size of the RMC	5
	Independent Directors (%)	20%
	Independent Director as Chairperson	No
	RMC Charter	Yes
Executive Remuneration	CEO-to-median remuneration of employee(FY21)	401.04
	Frequency: Annual declaration	Yes
Whistle Blower Policy	Number of whistle blower complaints received	0
	Whistle blower coverage - Employees	100%
	Whistle blower reporting mechanism - Email	Yes
	Whistle blower reporting mechanism - Letter	Yes
Taxation	Effective Tax Rate (%)	6.44%
	Cash Tax rate (%)	20.37%
SASB	Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries	٥
	Total amount of monetary losses as a result of legal proceedings associated with false marketing claims	0
	Number of Class I recalls (or equivalent)	1
	Number of Class II recalls (or equivalent)	11
	"Percentage change in:	"Percentage change in:
	(1) average list price and	(1) average list price : (-5.7%)
	(2) average net price across U.S. product portfolio comparedto previous year"	(2) average net price across U.S. product portfolio compared to previous year: (-10.6%)"
	Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery	0
Political Contributions	Contributions made to political campaigns, political organizations, lobbyists or lobbying organizations, trade associations and other tax-exempt groups	0



25 | ESG Report 2021-22











